Context Therapeutics CNTX
NASDAQ CNTX
$0.17 +0.00 (+0.00%)
At close: Nov 19, 2026 · 4:00 PM EST

Context Therapeutics (CNTX) Preferred Stock Liabilities (2020 - 2021)

Updated

Context Therapeutics (CNTX) recorded Preferred Stock Liabilities of $21.06 million in Q3 2021, up 203.4% from $6.94 million a year earlier and unchanged from the prior quarter.

Analysis

Context Therapeutics (CNTX) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends

At the end of FY2020, Context Therapeutics reported Preferred Stock Liabilities of $7.77 million.

  • Per Business Quant, the preceding three quarters came in at $21.06 million (Q2 2021), $16.36 million (Q1 2021) and $7.77 million (Q4 2020).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 PetVivo Holdings 3,096.39 Bn 3,096.39 Bn 196,075.00 -
2 Eli Lilly 1,202.70 Bn 1,176.32 Bn 20.46 Bn -
3 Johnson & Johnson 649.77 Bn 569.63 Bn 17.30 Bn -
4 AbbVie 507.00 Bn 475.00 Bn 13.12 Bn -
5 Merck 329.70 Bn 292.64 Bn 13.19 Bn -
6 Novartis Ag 291.91 Bn 265.14 Bn - -
7 Amgen 236.26 Bn 187.91 Bn 7.58 Bn -
8 Gilead Sciences 207.15 Bn 182.26 Bn 6.73 Bn -
9 Gsk 193.54 Bn 176.38 Bn - -
10 Context Therapeutics 15.24 Mn -182.70 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2021 21.06 Mn
Jun 30, 2021 21.06 Mn
Mar 31, 2021 16.36 Mn
Dec 31, 2020 7.77 Mn
Sep 30, 2020 6.94 Mn
API Access

Context Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=CNTX&period=max&api_key=YOUR_API_KEY